Latest Conference Articles

At the Greater Philadelphia Business Coalition on Health 2023 Wellness Summit, Seun Ross, PhD, explains the business case for achieving health equity.

"CMS cannot do this alone. We have to do this in partnership. So really thinking about providers and beneficiaries and how we do this together," Ellen Lukens, MPH, Center for Medicare and Medicaid Innovation, explained.

Laurie Sobel, the associate director for women’s health policy at KFF, moderated a panel discussion with Christine Gilroy, MD, MPH; Victoria Nichols, MPH; and Don Downing, RPh, about insurance coverage of FDA-approved Opill and other OTC contraceptives.

During this session at the National Comprehensive Cancer Network (NCCN) Policy Summit, Yelak Biru, MSc, and Crystal S. Denlinger, MD, explained the importance of screening for and addressing health-related social needs.

At the Greater Philadelphia Business Coalition on Health 2023 Wellness Summit, Vikki Walton, MBA, addresses the role employers have in health equity.

The combination demonstrated durable survival benefits among patients with metastatic non–small cell lung cancer (mNSCLC) regardless of PD-L1 expression levels at a minimum follow-up of more than 6 years.

Two abstracts presented at the 2023 International Epilepsy Congress evaluated early electroencephalography (EEG) monitoring in children with seizures and encephalopathy.

Care quality is high in both the United States and Canada, but there are commonalities in regard to drug access and cost issues, particularly with advanced medications, noted G. B. John Mancini, MD, University of British Columbia.

The final day of the European Society of Cardiology 2023 Congress featured a joint session with JAMA Cardiology, “Achieving Global Health Equity: A New Challenge in Heart Failure.”

Curing cancer is something we all want to do, but logistical issues remain around translating that into practice, explained Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.

Coverage from a symposium, “Weight loss as a new therapeutic target in HFpEF: dawn of a new era?” that took place August 27 during the European Society of Cardiology 2023 Congress.

Investigators conducted this subanalysis among patients aged 20 to 27 years, using data from the National Growth and Health Study to determine potential racial differences in left ventricular mass among female patients with obesity.

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

Javed Butler, MD, MPH, MBA, presented the analysis based on patient data from the Baylor, Scott, and White health system during the final hours of the European Society of Cardiology 2023 Congress, which concluded Monday.

There seems to be an institutional ignorance toward social determinants of health and actually making changes to improve outcomes for patients of color, said Shrilla Banerjee, MD, FRCP, consultant cardiologist, Surrey and Sussex Healthcare NHS Trust.

The EMPEROR trial showed that within 30 days of stopping empagliflozin, patients had a 70% higher risk of heart failure events, explained Milton Packer, MD, Baylor University Medical Center.

Results from the FRAIL-AF study, being presented at the European Society of Cardiology 2023 Congress, surprised the investigators.

Study investigators offered updated data from 2 key trials presented in the past year: CLEAR Outcomes in low-density lipoprotein cholesterol and OCEAN(a)-DOSE in lipoprotein (a).

Nikolaus Marx, MD, professor of medicine/cardiology and head of the Department of Internal Medicine, University Hospital Aachen, Germany, explains the new guidelines on screening for patients with type 2 diabetes and comorbid cardiovascular disease (CVD).

A symposium at the European Society of Cardiology 2023 Congress covered the spectrum from diet and exercise, to medical therapy, to evidence on newer generation stents.

When determining the success of cardiology therapies, trials should focus more on softer end points like quality of life and psychological well-being, said Donna Fitzsimons, PhD, FESC, professor of nursing at the School of Nursing and Midwifery, Queen's University Belfast.

Javed Butler, MD, MPH, MBA, said "hopefully" results from the EMPACT-MI trial should be available within the next few months.

There is a lot of drug switching that's happening, whether it's for medical or nonmedical reasons, said Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, professor of medicine at the University of Queensland.

With nearly a third of patients post-myocardial infarction (MI) developing heart failure, prevention is very important, said Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute.

Patients who took the therapy lost weight and recorded some of the best gains in quality of life and physical improvement ever seen in this type of a study.

The interim update in heart failure reflects results from 10 clinical trials that have been published since the 2021 ESC Guidelines were released.

Lucio Gordan, MD, president and managing physician, Florida Cancer Specialists & Research Institute (FCS), discusses how FCS has learned to adapt during difficult times, including COVID-19, Hurricane Ian, and current drug shortages.

Attendees should look out for results from the STEP HFpEF program and HEART-FID trial at the European Society of Cardiology (ESC) Congress 2023, said Stephen Greene, MD, Duke University Medical Center and the Duke Clinical Research Institute.

Data from the 1999-2018 National Health and Nutrition Examination Survey were used to analyze the prevalence of social determinants of health (SDOH) among patients with self-reported heart failure (HF).

Ahead of the European Society of Cardiology (ESC) Congress 2023, John McMurray, MD, FRCP, FESC, professor of medical cardiology at the University of Glasgow, previews some themes and important topics that will be discussed at the meeting.